Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04557384 · ClinicalTrials.gov registry record · Phase 1
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04557384: Clinical Trial Phase 1 study, sponsored by Eli Lilly and Company.
NCT04557384 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04557384, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.
Primary Outcome
PK: AUC of Ramucirumab over the dosing interval was evaluated. Cycle = 21 days.
Interventions
- DRUG Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2021-05-25 |
| Phase | Phase 1 |
Why NCT04557384 stopped before completion
NCT04557384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Ramucirumab is the first listed.
NCT04557384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04557384 about?
NCT04557384 is a clinical study titled "A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer". The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.
What is the current status of trial NCT04557384?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-02-23. Estimated completion is 2021-05-25.
What interventions are being tested in trial NCT04557384?
The interventions under investigation include: Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT04557384?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04557384's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI